Amol Akhade: New and exciting data coming up at WLCC 24
Amol Akhade shared on X about recent papers:
“What’s new and exciting data coming up at WLCC 24 .
1. Perioperative vs Neoadjuvant Nivo. Patient level data analysis.
2. Osimertinib with or without Savolitinib for met aberrant EGFR mutated 1st line NSCLC
3. Aumolertinib maintenance after CTRT for stage 3 NSCLC (polestar)
4. Ivonescimab vs pembrolizumab for PDL1 postive advanced NSCLC first line -Harmoni-2 trial
Source: Amol Akhade/X
Other posts featuring Amol Akhade on OncoDaily.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors.
He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.